Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any l... by Martin Forster, Joseph Sacco, Kenrick Ng, Laura White, Anthony Kong, Joseph Ward, Helen Lowe, John Hartley, Graham Wheeler, Rob Metcalf, Sharon Forsyth, Reshma Bhat, Leah Ensell, Victoria Spanswick, Elizabeth Lloyd-Dehler

Get full text